Regeneron CEO Takes Industry Counterview On FTC News: “I’m Glad They’re Looking Into This”
Executive Summary
Leonard Schleifer said it is time for US regulators to review whether certain rebate practices are anti-competitive, while speaking at the Financial Times US Pharma & Biotech Summit.
You may also be interested in...
Industry Leaders Speculate On FTC Vs. Amgen/Horizon Fallout
Pfizer chief clinical officer William Pao, Roche pharma CEO Teresa Graham and others weighed in on what FTC’s action could mean for pharma M&A at the Financial Times Pharma Summit.
Industry Leaders Speculate On FTC Vs. Amgen/Horizon Fallout
Pfizer chief clinical officer William Pao, Roche pharma CEO Teresa Graham and others weighed in on what FTC’s action could mean for pharma M&A at the Financial Times Pharma Summit.
FTC’s Challenge Of Amgen/Horizon Merger Seeks To Fight Pharma Rebating Practices
The US Federal Trade Commission is taking a stand against rebating and bundling practices pharma companies use in negotiations with payers as it seeks to block Amgen’s $28bn acquisition of Horizon.